Retrospective Analysis of HER2+ Breast Cancer Outcomes at a County Hospital: Do Published Outcomes Hold up in the Real World?

Introduction: Landmark trials repeatedly demonstrate that pertuzumab and trastuzumab plus standard chemotherapy have the best outcomes in human epidermal growth factor receptor 2 (HER2) positive breast cancer in the neoadjuvant, adjuvant, and metastatic setting. However, many of these multicenter la...

Descripción completa

Detalles Bibliográficos
Autores principales: Tareen, Serene A, Rodriguez, Joshua, Bolos, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Preventive Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266367/
https://www.ncbi.nlm.nih.gov/pubmed/32499977
http://dx.doi.org/10.7759/cureus.7937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266367/
https://www.ncbi.nlm.nih.gov/pubmed/32499977
http://dx.doi.org/10.7759/cureus.7937

Ejemplares similares